Ralpancizumab

Ralpancizumab (INN;[1] development code RN317) is a monoclonal antibody designed for the treatment of dyslipidemia.[2]

Ralpancizumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetneural apoptosis-regulated proteinase 1
Clinical data
Other namesRN317
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6422H9922N1730O2012S54
Molar mass145289.36 g·mol−1

This drug was developed by Pfizer.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.